| Identification | More | [Name]
DIPROTIN A | [CAS]
90614-48-5 | [Synonyms]
Diprotin
DIPROTIN A
ILE-PRO-ILE
DIPROTIN A H2O
Ile-Pro-Ile-OH
ILE-PRO-ILE H2O
H-ILE-PRO-ILE-OH
H-ILE-PRO-ILE-OH H2O
L-Ile-L-Pro-L-Ile-OH
Diprotin A (Ile-Pro-Ile)
L-Isoleucyl-L-prolyl-L-isoleucine
DIPEPTIDYLPEPTIDASE IV INHIBITOR I
L-Isoleucine, L-isoleucyl-L-prolyl-
n-(1-l-isoleucyl-l-prolyl)-l-isoleucin
n-(1-l-isoleucyl-l-prolyl)-l-isoleucine
N-(N-L-Isoleucyl-L-prolyl)-L-isoleucine
L-Isoleucine, N-(1-L-isoleucyl-L-prolyl)-
ILE-PRO-ILE;L-ISOLEUCYL-L-PROLYL-L-ISOLEUCINE | [Molecular Formula]
C17H31N3O4 | [MDL Number]
MFCD00038707 | [Molecular Weight]
341.45 | [MOL File]
90614-48-5.mol |
| Chemical Properties | Back Directory | [Boiling point ]
583.1±50.0 °C(Predicted) | [density ]
1.140±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
DMSO:250.0(Max Conc. mg/mL);732.17(Max Conc. mM)
Water:67.08(Max Conc. mg/mL);196.44(Max Conc. mM) | [form ]
White to off-white solid. | [pka]
3.72±0.22(Predicted) | [color ]
White to off-white | [Water Solubility ]
Soluble in water at 1mg/ml | [Usage]
New dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | [CAS DataBase Reference]
90614-48-5(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
Ile-Pro-Ile has been used as a supplement for blood collection for hormone measurement and used in Islets cell culture to stabilize glucagon-like peptide-1 (GLP-1). It has also been used to inhibit the breakdown of gonadotropin-inhibitory hormone (GnIH) following serum collection. | [Uses]
As New dipeptidyl peptidase IV inhibitors (Diprotin A) and their uses as anti-cancer agents
| [Definition]
ChEBI: (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid is a peptide. | [Biochem/physiol Actions]
Inhibitor of dipeptidyl peptidase IV. Inhibits entry of HIV-1 or HIV-2 into T lymphoblastoid and monocytoid cell lines. | [in vivo]
Diprotin A (intraperitoneal injection; 70?μg/kg; twice daily; 7 days) increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway[1]. | Animal Model: | Streptozotocin-induced diabetic retinopathy model in wild-type C57/BL6 mice[1] | | Dosage: | 70?μg/kg | | Administration: | Intraperitoneal injection; twice daily; 7 days | | Result: | Induced vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway. |
| [IC 50]
DPP-4 | [storage]
Store at -20°C |
|
|